A low-cost intranasal vaccine that offers universal protection against pneumococcal infections.
PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will consist of Outer Membrane Vesicles (OMVs), displaying fragments of novel conserved protein antigens. These antigens will warrant universal protection against all pneumococcal serotypes and can be delivered via intranasal administration. If successful, this next-generation vaccine will be able to decrease the incidence of pneumococcal diseases worldwide.
1 971 360.00€
Pharmaceutical Products / Drugs
Drug delivery and other equipment (including kidney dialysis machines)